220 related articles for article (PubMed ID: 35710462)
1. Skin cancers under Janus kinase inhibitors: A World Health Organization drug safety database analysis.
Jalles C; Lepelley M; Mouret S; Charles J; Leccia MT; Trabelsi S
Therapie; 2022; 77(6):649-656. PubMed ID: 35710462
[TBL] [Abstract][Full Text] [Related]
2. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.
Hoisnard L; Lebrun-Vignes B; Maury S; Mahevas M; El Karoui K; Roy L; Zarour A; Michel M; Cohen JL; Amiot A; Claudepierre P; Wolkenstein P; Grimbert P; Sbidian E
Sci Rep; 2022 May; 12(1):7140. PubMed ID: 35504889
[TBL] [Abstract][Full Text] [Related]
3. Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System.
Dong Z; Ye X; Chen C; Wang R; Liu D; Xu X; Zhou X; He J
Br J Clin Pharmacol; 2022 Sep; 88(9):4180-4190. PubMed ID: 35466415
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System.
Liu T; Gao R; Li L; Wu B; Wu F
Int J Clin Pharm; 2023 Dec; 45(6):1483-1491. PubMed ID: 37606843
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus reactivation associated with Janus kinase (JAK) inhibitors: a retrospective study of pharmacovigilance databases and review of the literature.
Pan C; Cao M; Yan C; Ou X; Zhang X; Xu W; Xu Y; Cui X
Expert Opin Drug Saf; 2023; 22(6):469-476. PubMed ID: 36794347
[TBL] [Abstract][Full Text] [Related]
6. Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase.
Vallejo-Yagüe E; Weiler S; Micheroli R; Burden AM
Drug Saf; 2020 Sep; 43(9):881-891. PubMed ID: 32533433
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022.
Wang Y; Cui C; Deng L; Wang L; Ren X
Front Immunol; 2023; 14():1127128. PubMed ID: 37292205
[TBL] [Abstract][Full Text] [Related]
8. Drugs associated with epidermal necrolysis in children: A World Health Organization pharmacovigilance database analysis.
Bataille P; Lebrun-Vignes B; Bettuzzi T; Ingen-Housz-Oro S; Hadj-Rabia S; Welfringer-Morin A; Bodemer C
J Eur Acad Dermatol Venereol; 2024 Apr; ():. PubMed ID: 38682703
[TBL] [Abstract][Full Text] [Related]
9. Association of Nonmelanoma Skin Cancers, Melanoma, and Merkel Cell Carcinoma with Dermatologic Medications: A Case-Control Pharmacovigilance Study of the FDA Adverse Events Reporting System.
Jedlowski PM
Dermatology; 2023; 239(5):694-699. PubMed ID: 37054693
[TBL] [Abstract][Full Text] [Related]
10. A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database.
Kim JE; Park J; Song TJ
Mult Scler; 2022 Nov; 28(13):2112-2123. PubMed ID: 35822296
[TBL] [Abstract][Full Text] [Related]
11. Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS).
Mytheen S; Varghese A; Joy J; Shaji A; Tom AA
Expert Opin Drug Saf; 2023; 22(10):985-994. PubMed ID: 37294921
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
Wei D; Chen Y; Shen Y; Xie B; Song X
Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021.
Wang Y; Cui C; Ren X; Dong X; Cui W
Front Cardiovasc Med; 2022; 9():988013. PubMed ID: 36312283
[TBL] [Abstract][Full Text] [Related]
15. Skin cancer signal associated with phosphodiesterase inhibitors: gaining insight through the FDA pharmacovigilance database.
Chow JW; Yan MM; Zhao H; Li ZR; Zhang Q; Zhong MK; Qiu XY
Expert Opin Drug Saf; 2023; 22(5):433-441. PubMed ID: 36334066
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced Stevens-Johnson syndrome: a disproportionality analysis from the pharmacovigilance database of the World Health Organization.
Zheng Y; Zhou W; Guo X; Chi L; Chen C; Guo Z; Liang J; Wei L; Chen X; Ye X; He J
Expert Opin Drug Saf; 2022 Aug; 21(8):1127-1133. PubMed ID: 35196201
[TBL] [Abstract][Full Text] [Related]
17. Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database.
Chen X; Wei L; Chi L; Guo X; Chen C; Guo Z; Liang J; Zheng Y; He J; Ye X
Br J Clin Pharmacol; 2022 May; 88(5):2180-2189. PubMed ID: 34786743
[TBL] [Abstract][Full Text] [Related]
18. Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.
Rastrelli M; Ferrazzi B; Tropea S; Costa A; Finotto S; Marino D; Campana L; Del Fiore P; Rossi CR; Alaibac M
In Vivo; 2019; 33(5):1667-1669. PubMed ID: 31471421
[TBL] [Abstract][Full Text] [Related]
19. Janus Kinase Inhibitors and Non-Melanoma Skin Cancer.
Greif CS; Srivastava D; Nijhawan RI
Curr Treat Options Oncol; 2021 Jan; 22(2):11. PubMed ID: 33423161
[TBL] [Abstract][Full Text] [Related]
20. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
